Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
BGNE BeiGene
215.650-10.200-4.52%
Close
03/22 16:00 ET
High
222.150
Open
222.150
Turnover
19.48M
Low
215.650
Pre Close
225.850
Volume
88.99K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Zymeworks a Buy at Wells Fargo on Royalty Streams, Future Milestones
BeiGene Hits Construction Milestone for Manufacturing, R&D Facility in New Jersey
08:30 AM EDT, 03/21/2023 (MT Newswires) -- BeiGene (BGNE) said Tuesday that it has reached a construction milestone for its manufacturing and R&D facility in Hopewell, New Jersey. The biotechnology co
StockNews.com Begins Coverage on BeiGene (NASDAQ:BGNE)
Equities researchers at StockNews.com began coverage on shares of BeiGene (NASDAQ:BGNE – Get Rating) in a report released on Thursday. The firm set a "hold" rating on the stock.Other analysts also rec
BeiGene Will Not Go Forward With Licensing Pact For Leap Therapeutics' Lead Cancer Candidate
Leap Therapeutics Inc (NASDAQ:LPTX) announced BeiGene Ltd's (NASDAQ:BGNE) option under the Exclusive Option, and License Agreement granting rights in certain Asian territories to DKN-01 has expired.Th
BeiGene State: Audit Committee Meeting Dates
Leap Therapeutics Provides Update on BeiGene Option Agreement For DKN-01; Says BeiGene's Option Under Exclusive Option And License Agreement Has Expired
Leap Therapeutics Provides Update on BeiGene Option Agreement For DKN-01; Says BeiGene's Option Under Exclusive Option And License Agreement Has Expired
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01
DisTinGuish Trial of DKN-01 plus tislelizumab and chemotherapy to continue as a clinical collaboration CAMBRIDGE, Mass., March 16, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company
Asian Equities Remain Flat in Thursday Trading
10:46 AM EDT, 03/16/2023 (MT Newswires) -- Asian equities were slightly higher in Thursday morning trading as American depositary receipts of Asian stocks nudged 0.18% higher to 1,491.39 on the S&P As
BeiGene (NASDAQ:BGNE) Shares Gap Up to $231.32
BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) gapped up prior to trading on Wednesday . The stock had previously closed at $231.32, but opened at $240.23. BeiGene shares last traded at $237.49, with a volu
Prelude Therapeutics Forms Hematologic Cancer Clinical Trial Partnership With BeiGene
10:45 AM EDT, 03/15/2023 (MT Newswires) -- Prelude Therapeutics (PRLD) said Wednesday it formed a clinical trial partnership for future evaluation of its experimental PRT2527 drug in combination with
